

# SOLUTIONS FOR HEALTHCARE

CENACLE RESEARCH

# ABOUT US

- Cenacle Research Offers a variety of Healthcare solutions crafted to the needs of:
  - Individuals (Patients)
  - Care Providers (Hospitals)
  - Control & Monitoring Boards (Govt. and Statutory Boards)
  - Participatory Entities (Labs, Drug Stores, Insurance Providers..)
  - System Integrators

# ABOUT US

- Cenacle Research Offers a variety of Healthcare solutions crafted to the needs of:
  - **Individuals (Patients)**
    - Personalized Healthcare
  - **Care Providers (Hospitals)**
    - Clinical Decision Support Systems
  - **Control & Monitoring Boards (Govt. and Statutory Boards)**
    - Population Health Analytics
    - Real-time Epidemic Outbreak Detection
  - **Participatory Entities (Labs, Drug Stores, Insurance Providers..)**
    - Order Prediction
    - Sales Analysis
  - **System Integrators**
    - Electronic Health Records
    - Health Information Exchange
    - Connected Experience

# POPULATION HEALTH ANALYTICS

Case Studies by Cenacle Research

# POPULATION HEALTH ANALYTICS

- Cenacle Research case studies:
  - Foodborne Disease Outbreak Detection
  - Disease Spread Causal Factor Analysis
  - Medicine Sales Cannibalization
  - Medicare Charge Disparity Analysis
  - Prioritization for Infectious Diseases





# FOODBORNE DISEASE OUTBREAK DETECTION

CASE STUDY

# FOODBORNE DISEASE OUTBREAK DETECTION

- Attribution of Food borne illnesses to Food Commodities
- *Goal:* Measuring probability and magnitude of disease outbreaks at a specific region and time based on food consumption and outbreak data
  - Government has a target for disease control – what is the probability that the targets can be met?

| Pathogen / Syndrome                               | Year  |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       |       | 2010 National health objective <sup>§</sup> | 2020 National health objective <sup>¶</sup> |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|---|---|
|   | 1996  | 1997  | 1998  | 1999  | 2000  | 2001  | 2002  | 2003  | 2004  | 2005  | 2006  | 2007  | 2008  | 2009  | 2010  | 2011  | 2012  |   |   |
| Surveillance population (millions) <sup>†††</sup> | 14.27 | 16.13 | 20.71 | 25.86 | 30.64 | 34.85 | 37.86 | 41.75 | 44.34 | 44.77 | 45.32 | 45.84 | 46.33 | 46.76 | 47.14 | 47.51 | 47.51 |   |   |
| Campylobacter                                     | 23.59 | 24.55 | 19.42 | 14.82 | 15.36 | 13.63 | 13.38 | 12.63 | 12.82 | 12.71 | 12.73 | 12.81 | 12.64 | 12.96 | 13.52 | 14.28 | 14.30 | 12.3  | 8.50  |
| Listeria <sup>**</sup>                            | 0.43  | 0.43  | 0.53  | 0.40  | 0.33  | 0.26  | 0.25  | 0.31  | 0.26  | 0.29  | 0.28  | 0.26  | 0.26  | 0.32  | 0.27  | 0.28  | 0.25  | 0.24  | 0.20  |
| Salmonella  | 14.46 | 13.55 | 13.61 | 16.07 | 14.08 | 15.04 | 16.24 | 14.46 | 14.65 | 14.53 | 14.76 | 14.89 | 16.09 | 15.02 | 17.55 | 16.45 | 16.42 | 6.8   | 11.40                                       |


# DATA

- Food borne disease historic data

| Year | Month     | State      | Genus Species       | Status    | Location Of Consumption | Total Ill | Total Hospitalizations | Total Death | FoodVehicle          |
|------|-----------|------------|---------------------|-----------|-------------------------|-----------|------------------------|-------------|----------------------|
| 1998 | June      | Washington |                     |           | Private home            | 2         |                        |             | chicken, unspecified |
| 1998 | August    | Washington | Vibrio cholerae     | Confirmed | Restaurant              | 2         | 0                      | 0           | oysters, unspecified |
| 1998 | September | Vermont    | Salmonella enterica | Confirmed | Other                   | 4         | 0                      | 0           |                      |

- Food classification data

- Food consumption data





# RESULTS

- Analytics model capable of predicting the probabilities of foodborne disease outbreaks with 86% accuracy
- Case in Point:
  - Successfully predicted the probability of 30 people getting ill due to consumption of leafy vegetables at picnic in Missisipi during September with Salmonella Entrica Infection






# DISEASE SPREAD CAUSAL FACTOR ANALYSIS

CASE STUDY

# DISEASE SPREAD CAUSAL FACTOR ANALYSIS

- Map disease spread to the factors affecting it
- *Goal:* Given the geographical, socio-economic factors and disease incidents, estimate the probability of a person getting affected by the disease
  - Control disease spread by controlling the causal factors affecting it



# DATA

- Drug sales
- Geographic data
  - Weather conditions, Seasonality, Pollution data etc.

| Rank | Drug  | Units (000) |
|------|---|-------------|
| 1    | <a href="#">budesonide</a><br>Generic Drug                | 22,605      |
| 2    | <a href="#">acetaminophen/hydrocodone</a><br>Generic Drug | 19,617      |
| 3    | <a href="#">omeprazole</a><br>Generic Drug                | 15,505      |

| Max 1-hour<br>NO2 | UNITS | DAILY_<br>AQI_V<br>ALUE | DAILY_<br>OBS_C<br>OUNT | PERCENT<br>_COMPL<br>ETE | AQS_PARA<br>METER_CO<br>DE | AQS_PARAMETER_DES<br>C | CSA_C<br>ODE |
|-------------------|-------|-------------------------|-------------------------|--------------------------|----------------------------|------------------------|--------------|
| 21.9              | ppb   | 20                      | 21                      | 88                       | 42602                      | Nitrogen dioxide (N    | 132          |
| 31.3              | ppb   | 29                      | 24                      | 100                      | 42602                      | Nitrogen dioxide (N    | 132          |
| 42.4              | ppb   | 40                      | 24                      | 100                      | 42602                      | Nitrogen dioxide (N    | 132          |
| 38.3              | ppb   | 36                      | 22                      | 92                       | 42602                      | Nitrogen dioxide (N    | 132          |

- Socio-economic data
  - Population density, Age groups, Per-capita income size etc.

| Location      | Children 18<br>and under | Adults 19-64 | 65+        | 65-74      | 75+        |
|---------------|--------------------------|--------------|------------|------------|------------|
| United States | 78,379,000               | 188,005,800  | 41,506,800 | 23,383,300 | 18,123,400 |
| Alabama       | 1,215,700                | 2,871,600    | 640,000    | 357,500    | 282,500    |
| Alaska        | 201,100                  | 432,600      | 58,300     | 34,800     | 23,500     |
| Arizona       | 1,733,300                | 3,935,000    | 818,400    | 483,000    | 335,300    |
| Arkansas      | 732,600                  | 1,712,100    | 448,900    | 253,000    | 195,900    |
| California    | 9,880,600                | 23,148,800   | 4,340,800  | 2,454,700  | 1,886,100  |
| Colorado      | 1,315,900                | 3,090,100    | 580,300    | 323,000    | 257,300    |

# RESULTS

- Analytics model capable of mapping the diseases with their causal factors with 84% accuracy
- Case in Point:
  - Identifying the **factors** affecting the **lung disease** spread based on patient's **dietary** habits, living **geographical** circumstances, **socio-economic** factors, **family** conditions and past medical history.






# MEDICINE SALES CANNIBALIZATION

CASE STUDY

# MEDICINE SALES ANALYSIS

- Competition and Sales comparison within Medicine groups
- *Goal:* Find any cannibalization effects and demographic, age, sex associations and trends



# DATA

- Time series drug sales data

| Rank | Drug                      | Current Manufacturer                        | Total Rxs (000) | % Change 2003 |
|------|---------------------------|---|-----------------|---------------|
| 1    | <a href="#">Lipitor</a>   | <a href="#">Pfizer Inc</a>                  | 62,541          | 6.6%          |
| 2    | <a href="#">Synthroid</a> | <a href="#">Abbott Laboratories</a>         | 42,105          | -7.0%         |
| 3    | <a href="#">Norvasc</a>   | <a href="#">Pfizer Inc</a>                  | 30,929          | 4.3%          |
| 4    | <a href="#">Toprol XL</a> | <a href="#">AstraZeneca Pharmaceuticals</a> | 30,450          | 16.3%         |
| 5    | <a href="#">Zoloft</a>    | <a href="#">Pfizer Inc</a>                  | 28,755          | 0.6%          |
| 6    | <a href="#">Zocor</a>     | <a href="#">Merck &amp; Co., Inc.</a>       | 23,804          | -1.7%         |

- Demographic data
- Socio-economic data

| Characteristic                      | Total   | Under \$5,000 | \$5,000 to \$9,999 | \$10,000 to \$14,999 | \$15,000 to \$19,999 | \$20,000 to \$24,999 | \$25,000 to \$29,999 | \$30,000 to \$34,999 | \$35,000 to \$39,999 | \$40,000 to \$44,999 | \$45,000 to \$49,999 | \$50,000 to \$54,999 |
|-------------------------------------|---------|---------------|--------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| <b>All Races</b>                    |         |               |                    |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| All Households                      | 121,084 | 4,261         | 4,972              | 7,127                | 6,882                | 7,095                | 6,591                | 6,667                | 6,136                | 5,795                | 4,945                | 5,170                |
| <b>TYPE OF RESIDENCE</b>            |         |               |                    |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Inside metro statistical areas      | 101,526 | 3,565         | 3,961              | 5,658                | 5,469                | 5,665                | 5,263                | 5,463                | 5,032                | 4,800                | 4,173                | 4,289                |
| Inside principal cities             | 40,616  | 1,991         | 2,135              | 2,751                | 2,536                | 2,546                | 2,192                | 2,415                | 2,109                | 2,061                | 1,641                | 1,638                |
| Outside principal cities            | 60,910  | 1,574         | 1,825              | 2,907                | 2,933                | 3,119                | 3,070                | 3,048                | 2,923                | 2,739                | 2,532                | 2,651                |
| Outside metro statistical areas (4) | 19,558  | 697           | 1,012              | 1,468                | 1,413                | 1,430                | 1,329                | 1,205                | 1,104                | 995                  | 772                  | 881                  |
| <b>REGION/DIVISIONS</b>             |         |               |                    |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Northeast                           | 21,774  | 769           | 892                | 1,290                | 1,115                | 1,164                | 1,070                | 1,073                | 992                  | 1,000                | 775                  | 903                  |



# RESULTS

- Analytics model capable of revealing the sales cannibalization effects among similar class of drugs
- Results played important role in building personalized health regimes for chronic disease patients
  - Trends of cannibalization over period of time in similar class of drugs establishes generic trends of reception for group of patients forming cohorts






# MEDICARE CHARGE DISPARITY ANALYSIS

CASE STUDY

# MEDICARE CHARGE DISPARITY ANALYSIS

- *Goal:* Identify the culprit hospitals and the factors for the charge disparity



# DATA


- Inpatient discharge group data for 3100+ US hospitals
- Data for top 100 disease groups with average charges within each DRG
- Hospital infrastructure data

| F1 |     | Acute_Care_Hospital_Beds_per_1000_Residents |       |         |           |           |          |           |           |           |           |           |            |           |           |             |            |
|----|-----|---|-------|---------|-----------|-----------|----------|-----------|-----------|-----------|-----------|-----------|------------|-----------|-----------|-------------|------------|
|    | A   | B   | C     | D       | E         | F         | G        | H         | I         | J         | K         | L         | M          | N         | O         | P           | Q          |
| 1  | HRR | HRR_City                                    | State | Number_ | Resident_ | Acute_Car | Hospital | FTE_Hospi | Total_Phy | Primary_C | Total_Spe | Medical_S | Hospital-B | Surgeons_ | Resident_ | Allergists/ | Anesthetic |
| 2  | 1   | Birmingham                                  | AL    | 8554    | 2216270   | 3.46      | 4.15     | 15.1      | 177.3     | 63        | 111.8     | 37.4      | 22.2       | 41        | 35.4      | 0.72        | 9.15       |
| 3  | 2   | Dothan                                      | AL    | 3482    | 363788    | 3.33      | 4.32     | 16.3      | 154.6     | 53.7      | 98.5      | 30.6      | 21.9       | 40.7      | 6.7       | 0.91        | 9.16       |
| 4  | 5   | Huntsville                                  | AL    | 5348    | 571384    | 2.61      | 4.66     | 14.5      | 178.2     | 67.7      | 108       | 34.6      | 23         | 39.1      | 13.3      | 0.82        | 9.94       |
| 5  | 6   | Mobile                                      | AL    | 4638    | 795089    | 3.08      | 4.39     | 15.4      | 171.2     | 56.9      | 112       | 38.4      | 22.1       | 41.2      | 27.8      | 0.61        | 8.97       |
| 6  | 7   | Montgomery                                  | AL    | 3750    | 450233    | 2.74      | 3.6      | 11.3      | 155.2     | 61        | 91.8      | 29.4      | 19.7       | 35.8      | 13.5      | 1.05        | 6.97       |
| 7  | 9   | Tuscaloosa                                  | AL    | 3049    | 245113    | 3.52      | 4.83     | 17.8      | 181.2     | 67.7      | 111.1     | 36.4      | 21         | 35.7      | 25.6      | 1.59        | 7.97       |
| 8  | 10  | Anchorage                                   | AK    | 1661    | 666346    | 2.54      | 4.26     | 15.5      | 244.7     | 100.5     | 140.8     | 43.3      | 28.7       | 53.1      | 13.3      | 0.81        | 15.33      |

# RESULTS

- Analytical insights into the disease spend waste happening at population level
- Policy recommendations and infrastructural requirement guidelines for Medicare





# PRIORITIZATION FOR INFECTIOUS DISEASES

CASE STUDY

# PRIORITIZATION FOR INFECTIOUS DISEASES

- Classifying the most frequent pathogens in order of their significance for national surveillance and epidemiological research
- *Goal:* Create a basis for strategic and conceptual decisions in the field of infectious disease epidemiology
  - Goal is to come up with relative ranking rather than an absolute cut-off (beyond which diseases are not considered important)

| Criteria           | Values  |  |  |
|--------------------|---|--|--|
|                    | -1  | 0  | 1  |
|                    | <i>Burden of disease</i>  |  |  |
| Incidence          | < 1/100,000   | 1–20/100,000   | > 20/100,000   |
| Severity           | Hospitalization is rare, work loss is < 2 days, no persisting handicaps | Hospitalization is rare, work loss of > 5 days is rare, few persisting handicaps | Hospitalization is frequent, work loss of > 5 days is frequent, persisting handicaps occur |
| Mortality          | < 50 deaths/year in Germany   | 50–500 deaths /year in Germany   | > 500 deaths/year in Germany   |
|                    | <i>Epidemiological dynamic</i>  |  |  |
| Outbreak potential | Outbreaks are rare  | Outbreaks with five or more cases are rare                                       | Outbreaks with five or more cases are frequent   |
| Trend              | Diminishing incidence rates   | Stable incidence rates   | Increasing incidence rates   |
| Emerging potential | Disease already endemic or unlikely to be introduced to Germany         | Disease has the potential to be introduced to Germany sporadically               | Disease is likely to emerge in Germany in a relevant way                                   |

# DATA

- Notifiable diseases and pathogens data for Germany region.
  - Disease, Case category, compliance with the case definition
  - Reporting week, month, quarter, and year
  - Age group , Sex, Pathogen (e.g., serovar, phage type, etc.)

| Meldekategorie | klin.-<br>epidemiologisch | klin.-<br>labordiagnostisch | klinisch | labordiagn.<br>bei nicht<br>erfüllter<br>Klin. | labordiagn.<br>bei unbek.<br>Klin. |
|----------------|---------------------------|-----------------------------|----------|--|------------------------------------|
| Adenovirus     | 197                       | 1356                        | 0        | 0  | 0                                  |
| Botulismus     | 0                         | 5                           | 0        | 0  | 0                                  |
| Brucellose     | 0                         | 15                          | 0        | 0  | 0                                  |
| Campylobacter  | 243                       | 40408                       | 0        | 0  | 0                                  |
| Cholera        | 0                         | 1                           | 0        | 0  | 0                                  |
| CJK            | 0                         | 24                          | 39       | 5  | 0                                  |
| Denguefieber   | 0                         | 574                         | 0        | 0  | 0                                  |



# RESULTS

- Classification model prioritizing the pathogens in the order of their significance
- The relative ranking model provides the basis for formulating nation wide strategy for combating infectious disease monitoring, control and eradication



# SOLUTION LANDSCAPE

Cenacle Research

# SOLUTIONS LANDSCAPE

- **For Doctors**


- Clinical Decision Support System
  - Diagnostic Assistance
  - Treatment Guidance
  - Risk Assessment

- **For Patients**

- Personalized Healthcare System
  - Disease Modelling
    - Behavioural Patterns Analysis
    - Cohort Identification & Patient profiling
  - Personalized Insurance
- Electronic Health Records

- **System-wide**

- Health Information Exchange
- Real-time Monitoring & Population Health Indicators
  - Epidemic Outbreak Detection
  - Contagious Disease Spread Modelling
  - Farm-to-Fork Analysis
- Connected Experience



# SOLUTION LANDSCAPE: FOR DOCTORS

- Clinical Decision Support Systems (CDSS)
  - Intelligent algorithms capable of digesting the medical records and helping doctors in making right decisions
- Diagnostic Assistance
  - Based on the symptoms indicated by patient, CDSS identifies the most probable disease and suggests the right diagnostics to the Doctors
  - Eliminates redundant tests and avoids unnecessary costs, reducing the delay in treatment
- Treatment Guidance
  - Based on the Diagnostic results, helps Doctors identify and prescribe the right treatment personalized for each patient
- Risk Assessment
  - Helps the Doctor assess the risk of a potential treatment to a patient through the means of simulation

# SOLUTION LANDSCAPE: FOR PATIENTS

- Personalized Healthcare
  - A personalized medicine regime that is designed based on patient's living habits, socio-economic factors, living geographical conditions and past medical history
- Every individual is Unique
  - Not all drugs are suitable for all
  - Identifying differences between patients is critical to understanding the nature of illness
- Unity in Diversity
  - Diseases are united in their symptoms, but divided in their right cure for each patient
  - Cohort identification plays critical role in designing the right medicinal regime for each disease
- Our exploratory analysis techniques and advanced Monte Carlo simulation methods infer the right personalized healthcare model for each individual

Visit us @ <http://cenacle.co.in/>

CENACLE RESEARCH

Do More.